Functional Impact of the G279S Substitution in the Adenosine A 1 -Receptor (A 1 R-G279S 7.44 ), a Mutation Associated with Parkinson's Disease.

Autor: Nasrollahi-Shirazi S; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Szöllösi D; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Yang Q; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Muratspahic E; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., El-Kasaby A; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Sucic S; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Stockner T; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Nanoff C; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Freissmuth M; Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria michael.freissmuth@meduniwien.ac.at.
Jazyk: angličtina
Zdroj: Molecular pharmacology [Mol Pharmacol] 2020 Sep; Vol. 98 (3), pp. 250-266.
DOI: 10.1124/molpharm.120.000003
Abstrakt: In medium-size, spiny striatal neurons of the direct pathway, dopamine D 1 - and adenosine A 1 -receptors are coexpressed and are mutually antagonistic. Recently, a mutation in the gene encoding the A 1 -receptor (A 1 R), A 1 R-G279S 7.44 , was identified in an Iranian family: two affected offspring suffered from early-onset l-DOPA-responsive Parkinson's disease. The link between the mutation and the phenotype is unclear. Here, we explored the functional consequence of the G279S substitution on the activity of the A 1 -receptor after heterologous expression in HEK293 cells. The mutation did not affect surface expression and ligand binding but changed the susceptibility to heat denaturation: the thermodynamic stability of A 1 R-G279S 7.44 was enhanced by about 2 and 8 K when compared with wild-type A 1 -receptor and A 1 R-Y288A 7.53 (a folding-deficient variant used as a reference), respectively. In contrast, the kinetic stability was reduced, indicating a lower energy barrier for conformational transitions in A 1 R-G279S 7.44 (73 ± 23 kJ/mol) than in wild-type A 1 R (135 ± 4 kJ/mol) or in A 1 R-Y288A 7.53 (184 ± 24 kJ/mol). Consistent with this lower energy barrier, A 1 R-G279S 7.44 was more effective in promoting guanine nucleotide exchange than wild-type A 1 R. We detected similar levels of complexes formed between D 1 -receptors and wild-type A 1 R or A 1 R-G279S 7.44 by coimmunoprecipitation and bioluminescence resonance energy transfer. However, lower concentrations of agonist were required for half-maximum inhibition of dopamine-induced cAMP accumulation in cells coexpressing D 1 -receptor and A 1 R-G279S 7.44 than in those coexpressing wild-type A 1 R. These observations predict enhanced inhibition of dopaminergic signaling by A 1 R-G279S 7.44 in vivo, consistent with a pathogenic role in Parkinson's disease. SIGNIFICANCE STATEMENT: Parkinson's disease is caused by a loss of dopaminergic input from the substantia nigra to the caudate nucleus and the putamen. Activation of the adenosine A 1 -receptor antagonizes responses elicited by dopamine D 1 -receptor. We show that this activity is more pronounced in a mutant version of the A 1 -receptor (A 1 R-G279S 7.44 ), which was identified in individuals suffering from early-onset Parkinson's disease.
Competing Interests: The authors declare that they have no conflicts of interest with the contents of this article.
(Copyright © 2020 by The Author(s).)
Databáze: MEDLINE
Externí odkaz: